Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 11Carcinoma, Renal Cell 10Carcinoma, Non-Small-Cell Lung 6Prostatic Neoplasms 4Neoplasm Metastasis 4Myelodysplastic Syndromes 4Lung Neoplasms 4Clear-cell metastatic renal cell carcinoma 4Urinary Bladder Neoplasms 3Urethral Neoplasms 3Leukemia, Myeloid, Acute 3Histiocytoma, Malignant Fibrous 3Carcinoma, Transitional Cell 3Carcinoma, Basal Cell 3Urogenital Neoplasms 2Ureteral Neoplasms 2Thyroid Neoplasms 2Sarcoma 2Penile Neoplasms 2Ovarian Neoplasms 2Nasopharyngeal Carcinoma 2Glioblastoma 2Carcinoma, Merkel Cell 2Carcinoma, Endometrioid 2Brain Neoplasms 2Adenocarcinoma of Lung 2Vulvar Neoplasms 1Uveal Melanoma 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1

Interventions

Nivolumab 2cabozantinib 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urachal adenocarcinoma × CTLA-4 Antigen × 90 days × Clear all
NCT03866382 2026-06-03

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
314 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡